ENDPOINTS

As a challenging first half nears a close, biopharma uncertainty persists

What will the second half of 2025 bring for biopharma? It's a tough question to answer after a slog of stock-moving proposals out of Washington dampened the cheery sentiment at the start of the year ...

May 30, 2025 - 14:54
 0
As a challenging first half nears a close, biopharma uncertainty persists
What will the second half of 2025 bring for biopharma? It's a tough question to answer after a slog of stock-moving proposals out of Washington dampened the cheery sentiment at the start of the year ...
Read More

Tags:

Previous Article

Half the world faced an extra month of extreme heat due to climate change: study

Next Article

Researchers devise method to identify '311' underreporting of heat and hot water...

Related Posts

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Novo turns to Septerna for oral obesity medicines in de...

May 14, 2025  0

Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks $1B in funds

Retro Biosciences inks blood disorder deal as Sam Altma...

May 20, 2025  0

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

Roche’s 96-week data for multiple sclerosis drug; ZymeW...

May 30, 2025  0